Absci Corporation · NASDAQ:ABSI

Absci — 42nd J.P. Morgan Healthcare Conference (January 2024)

22 slides from Absci's conference presentation, January 2024

Slide 2: Disclaimers
Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including state
Slide 3: Absci is a Data-First Generative AI Drug Creation Company
Absci is a Data-First RECENT SUCCESSES Generative AI Drug N E W P H A R M A PA R T N E R S H I P S Creation Company • “Astrazeneca Types up $247m AI-enabled Oncology Antibody Design Pact, Joining Absci’s list of Pharma Allies” – Fierce Pharma Our Integrated AI & Wet Lab Platform • “Skin in the Game:
Slide 4: Integrated Wet-Lab Dry-Lab Drug Creation Platform
Integrated Wet-Lab Dry-Lab Drug CreationTM Platform Proprietary wet-lab assays generate massive quantities of high-quality data for generative AI model training Scalable wet-lab infrastructure Advanced generative AI capable of validating millions of models used to “create” unique AI-generated design
Slide 5: Proprietary Wet-lab Technologies Generate High-quality Data at Scale
Proprietary Wet-lab Technologies Generate High-quality Data at Scale DATA TO TRAIN Absci’s AI capable of creating billions of antibody designs for our proprietary models and ACE Assay™ technology to subsequently screen millions of ranked antibody sequences in weeks. SOLUPRO™ ABSCI’S ACE CELL LINE AS
Slide 6: Advanced generative AI models to "create" biologics in silico
Advanced generative AI models to “create” biologics in silico AI TO CREATE Generative AI models utilizing latest architectural innovations to access a massive ~20^55 sequence search space to design antibody-antigen complex structures and sequences in silico Target Antigen Structure INPUT OUTPUT AI d
Slide 7: Wet-lab Capable of Validating Millions of AI-Generated Designs in a Week
Wet-lab Capable of Validating Millions of AI-Generated Designs in a Week WET LAB TO VALIDATE 77,000 SqFt+ Wet-Lab to generate scalable data and validate AI-generated designs in rapid iterative 6-week cycles FUNCTIONALITY DEVELOPABILITY • Binding Affinity • Self association • Specificity to target(s)
Slide 8: Leveraging AI Throughout the End-to-End Drug Discovery Process
INTEGRATED AI WET-LAB PLATFORM Leveraging AI Throughout the End-to-End Drug Discovery Process TARGET DISCOVERY WITH AI-GUIDED ANTIBODY DRUG AI-GUIDED LEAD NOVEL APPROACHES CREATION OPTIMIZATION Reverse Immunology for target De novo antibodies designed by AI Multi-parameteric optimized discovery anti
Slide 9: Platform Enables the Potential to Deliver Differentiated Biologics, Faster at Lower Cost
VALUE DRIVERS Platform Enables the Potential to Deliver Differentiated Biologics, Faster at Lower Cost ACCESS NOVEL INCREASED REDUCED TIME & EXPANDED DISEASE BIOLOGY PROBABILITY COST TO CLINIC INTELLECTUAL OF SUCCESS PROPERTY SPACE Ability to address elusive Superior Drug Attributes 2 years and $14-
Slide 10: Over $900M + Royalties of Potential Deal Value Signed in the Last 2 Months
RECENT PARTNERSHIPS Over $900M + Royalties of Potential Deal Value Signed in the Last 2 Months I L LU S T R AT I V E E C O N O M I C S T R U C T U R E O F A S U C C E S S F U L D R U G D I S C OV E R Y PA R T N E R S H I P DEC 04, 2023 “Astrazeneca Types up $247m AI-enabled Oncology Antibody Design
Slide 11: Driving Growth Through Industry-Leading Collaborations
PARTNERSHIPS Driving Growth Through Industry-Leading Collaborations including 16 Active Programs1 and 3 Internal Programs 3 Internal Programs with Potential AI DRUG DISCOVERY Best-in -Class or First-in - Class Profile COLLABORATIONS DATA & COMPUTE INTERNAL ASSET COLLABORATIONS PIPELINE COLLABORATION
Slide 12: Internal Pipeline of Potential First-in-Class and Best-in-Class Assets
SELECT PIPELINE HIGHLIGHTS Internal Pipeline of Potential First-in-Class and Best-in-Class Assets Focus on cytokine biology - first frontier of AI-driven disruption THERAPEUTIC AREA/ TARGET TARGET VAL LEAD CANDIDATE IND-ENABLING IND INFL. BOWEL DISEASE / TL1A ABS-101 DERMATOLOGY / UNDISCLOSED ABS-20
Slide 13: ABS-101 Clinically Validated Mechanism of Action in Large Underserved Market
ABS-101 TL1A DATA HIGHLIGHTS Clinically Validated Mechanism of Action in Large Underserved Market TL1A: DR3 SIGNALING CLINICALLY SHOWN TO POTENTIAL RELEVANCE IN WIDE INDUCE PRO-INFLAMMATORY RESPONSES1 RANGE OF AUTOIMMUNE INDICATIONS 5M Global Inflammatory Significant market Bowel Disease (IBD) oppor
Slide 14: Potential Best-in-Class TL1A mAb Designed using Generative AI
ABS-101 TL1A DATA HIGHLIGHTS Potential Best-in-Class TL1A mAb Designed using Generative AI DE NOVO AI-DESIGNED AND AI-OPTIMIZED • Target to promising candidates in just over 1 year SUPERIOR PRE-CLINICAL PROFILE AND POTENTIAL FOR SUPERIOR CLINICAL PROFILE AI-designed TL1A • High Affinity & Potency pr
Slide 15: AI Platform Designed Advanced Leads with High Affinity and Superior Potency
ABS-101 TL1A DATA HIGHLIGHTS AI Platform Designed Advanced Leads with High Affinity and Superior Potency HIGH AFFINITY mABs WITH PRESERVED AI-OPTIMIZED LOW pM AFFINITY TRANSLATES CROSS-REACTIVITY TO SUPERIOR OR EQUIVALENT POTENCY AFFINITY BY SURFACE PLASMON RESONANCE (SPR) APOPTOSIS INHIBITION ASSAY
Slide 16: AI Platform Designed Advanced Leads with Extended Half-life
ABS-101 TL1A DATA HIGHLIGHTS AI Platform Designed Advanced Leads with Extended Half-life: Supporting Potential for Significantly Improved Dosing Intervals EXTENDED HALF-LIFE IN VITRO COMPARED TO PRELIMINARY IN VIVO PK DATA SHOWS CLINICAL COMPETITORS POTENTIAL FOR EXTENDED HALF-LIFE INCREASED RECYCLI
Slide 17: AI Platform Designed Leads Span Diverse Set of Epitopes
ABS-101 TL1A DATA HIGHLIGHTS AI Platform Designed Leads Span Diverse Set of Epitopes Leading to IP Differentiation Epitope bins* on TL1A Absci AI-optimized leads span ABS-101-A multiple epitopes RVT-3101 # ABS-101 binds a unique epitope on ABS-101-C TL1A, differentiating ABS-101 from MK-7240 # clini
Slide 18: ABS-101 Aims for Optimal Therapeutic Profile
ABS-101 TL1A DATA HIGHLIGHTS AI Platform Designed ABS-101 Aims for Optimal Therapeutic Profile MERCK SANOFI ABS-101 ROCHE (ROIVANT) ATTRIBUTE (PROMETHEUS) (TEVA) PROGRAM* RVT-3101 MK-7240 TEV-48574 Low - 1,5   1 Immunogenicity** - 1, 4   1 High Bioavailability Sub-Q    2 3 autoinjector 1, 3 1
Slide 19: Projected Timeline to Potential Best-in-Class Molecule
ABS-101 TL1A DATA HIGHLIGHTS P ro jected T im eline to P o ten tial Best- in - C lass M o lecu le TODAY INITIATING FEB ‘24 1Q25 1H25 AI-Designed Advanced Leads IND-enabling studies to evaluate Investigational New Initiating Phase 1 Trial Drug (IND) Submission  High Affinity • Sub-Q formulation  Hi
Slide 20: Absci's talent and Infrastructure for Better Biologics Faster, at Lower Cost
WELL-POSITIONED TO DELIVER Absci’s talent and Infrastructure for Better Biologics Faster, at Lower Cost Unlimiters with deep experience in AI, drug discovery, ~ 160 immunology, and synthetic biology Leading AI team with expertise from: Biologics drug discovery expertise from: 77,000+ State-of-the-ar
Slide 21: Leadership Team of Innovators Across AI and Biotech
WORLD-CLASS TEAM Leadership Team of Innovators Across AI and Biotech to Transform Drug Discovery LEADERSHIP TEAM BOARD OF DIRECTORS SEAN MCCLAIN ANDREAS BUSCH, PHD ZACH JONASSON, PHD KARIN WIERINCK JACK GOLD KAREN MCGINNIS, CPA FRANS VAN HOUTEN SIR MENE PANGALOS, PHD Founder, CEO & Director Chief In
Slide 22: Better Biologics Faster and at Lower Cost
Better Biologics Faster and at Lower Cost ‘Data to Train’, ‘AI to Create’, and ‘Wet Lab to Validate’ in rapid 6-week cycles IND submission for U P C O M I N G C ATA LY T S & ABS-101 in 1Q25 Platform validated through industry- C O N T I N U E D PA R T N E R S H I P leading partnerships, most recentl

Absci — 42nd J.P. Morgan Healthcare Conference (January 2024) on 6ix

Absci — 42nd J.P. Morgan Healthcare Conference (January 2024)

Slide 1: 42nd JP Morgan Healthcare Conference

Slide 2: Disclaimers

Slide 3: Absci is a Data-First Generative AI Drug Creation Company

Slide 4: Integrated Wet-Lab Dry-Lab Drug Creation Platform

Slide 5: Proprietary Wet-lab Technologies Generate High-quality Data at Scale

Slide 6: Advanced generative AI models to "create" biologics in silico

Slide 7: Wet-lab Capable of Validating Millions of AI-Generated Designs in a Week

Slide 8: Leveraging AI Throughout the End-to-End Drug Discovery Process

Slide 9: Platform Enables the Potential to Deliver Differentiated Biologics, Faster at Lower Cost

Slide 10: Over $900M + Royalties of Potential Deal Value Signed in the Last 2 Months

Slide 11: Driving Growth Through Industry-Leading Collaborations

Slide 12: Internal Pipeline of Potential First-in-Class and Best-in-Class Assets

Slide 13: ABS-101 Clinically Validated Mechanism of Action in Large Underserved Market

Slide 14: Potential Best-in-Class TL1A mAb Designed using Generative AI

Slide 15: AI Platform Designed Advanced Leads with High Affinity and Superior Potency

Slide 16: AI Platform Designed Advanced Leads with Extended Half-life

Slide 17: AI Platform Designed Leads Span Diverse Set of Epitopes

Slide 18: ABS-101 Aims for Optimal Therapeutic Profile

Slide 19: Projected Timeline to Potential Best-in-Class Molecule

Slide 20: Absci's talent and Infrastructure for Better Biologics Faster, at Lower Cost

Slide 21: Leadership Team of Innovators Across AI and Biotech

Slide 22: Better Biologics Faster and at Lower Cost